Consolidated Statements of Cash Flows - USD ($)		3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Jul. 29, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2021	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash Flows From Operating Activities:
Net loss		$ (4,490,000)	$ (4,477,000)		$ (8,750,000)	$ (13,240,000)	$ (19,685,000)	$ (14,268,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation					225,000	346,000	475,000	416,000
Income tax benefit		(335,000)	(532,000)		(532,000)	(867,000)	(1,425,000)	0
Change in fair value of contingent consideration					(442,000)	(244,000)	2,091,000	0
Right of use asset					90,000	137,000	183,000	166,000
Depreciation					36,000	60,000	85,000	87,000
Changes in operating assets and liabilities:
Prepaid expenses and other current assets					518,000	780,000	(363,000)	174,000
Accounts payable					(295,000)	(504,000)	(385,000)	(363,000)
Accrued expenses					265,000	(326,000)	(267,000)	1,004,000
Accrued employee benefits					(272,000)	271,000	333,000	110,000
Lease liability					(101,000)	(127,000)	(124,000)	(216,000)
Net Cash Used In Operating Activities					(9,258,000)	(13,714,000)	(19,082,000)	(12,890,000)
Cash Flows From Investing Activities:
Purchases of property and equipment					(14,000)	(25,000)	(116,000)	(14,000)
Cash paid for business combination; net of cash acquired					(3,863,000)	(3,863,000)	(3,863,000)	0
Pre-acquisition loan to VCN					(417,000)	(417,000)	(417,000)	0
Net Cash Used In Investing Activities					(4,294,000)	(4,305,000)	(4,396,000)	(14,000)
Cash Flows From Financing Activities:
Payment of debt					(1,376,000)		(1,376,000)	0
Proceeds from sale of series preferred stock, net of issuance cost	$ 3,000,000.0
Payment of contingent consideration							(3,000,000)
Purchase of treasury stock							(288,000)	0
Proceeds from "at-the-market" stock issuance							0	65,960,000
Proceeds from issuance of common stock for warrant exercises				$ 8,000,000.0			0	8,042,000
Net Cash (used in) Provided By Financing Activities					(1,376,000)	1,358,000	(1,930,000)	74,002,000
Effects of FX on cash					(35,000)	(84,000)	(32,000)	0
Net (decrease) increase in cash and cash equivalents and restricted cash					(14,963,000)	(16,661,000)	(25,408,000)	61,098,000
Cash and cash equivalents and restricted at the beginning of this period		52,362,000		$ 6,227,000	67,325,000	67,325,000	67,325,000	6,227,000
Cash and cash equivalents and restricted cash at the end of this period		50,580,000	52,362,000		52,362,000	50,580,000	41,885,000	67,325,000	$ 6,227,000
Reconciliation of cash, cash equivalents, and restricted cash reported in the statement of financial position
Cash and cash equivalents		50,490,000	52,266,000		52,266,000	50,490,000	41,786,000	67,325,000
Restricted cash included in other long-term assets		90,000	96,000		96,000	90,000	99,000	0
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows		$ 50,580,000	$ 52,362,000		52,362,000	50,580,000	41,885,000	67,325,000	6,227,000
Supplemental non-cash investing and financing activities:
Fair value of contingent consideration issued in a business combination					12,158,000	12,158,000	10,093,000	0
Fair value of equity issued as consideration in a business combination					6,599,000	6,599,000	6,599,000	0
Effective settlement of pre-closing VCN financing					417,000	417,000	417,000	0
Goodwill measurement period adjustment					$ 277,000	(884,000)	(1,061,000)	0
In-process R&D measurement period adjustment						810,000	810,000	0
Deferred tax liability measurement period adjustment						202,000	202,000	0
Effect of Warrant exercise price adjustment						340,000	340,000	0	$ 900,000
Effect of Series A Preferred Stock price adjustment							0	7,402,000
Return of SYN Biomics Stock							0	2,774,000
Deemed dividends for accretion of Series B Preferred Stock discount							0	1,496,000
Right of use assets from operating lease							0	1,270,000
In-kind dividends in preferred stock							0	24,000
Series C Preferred Stock
Cash Flows From Financing Activities:
Payment of debt						(1,376,000)
Proceeds from sale of series preferred stock, net of issuance cost						2,006,000	2,006,000	0
Series D Preferred Stock
Cash Flows From Financing Activities:
Proceeds from sale of series preferred stock, net of issuance cost						$ 728,000	728,000	0
Series A Preferred Stock
Supplemental non-cash investing and financing activities:
Conversion of Preferred Stock							0	12,822,000
Effect of Series A Preferred Stock price adjustment								7,402,000
Series B Preferred Stock
Supplemental non-cash investing and financing activities:
Conversion of Preferred Stock							$ 0	$ 2,477,000